Outcomes of Kidney Retransplantation after Graft Loss due to BK Virus Nephropathy in the Era of Newer Immunosuppressant Agents.
We conducted this study using the updated 2005-2016 UNOS database to assess clinical outcomes of retransplantation after allograft loss due to BK virus-associated nephropathy (BKVAN). 341 patients had first graft failure due to BKVAN, whereas 13,260 had first graft failure due to other causes. At median follow-up time of 4.70 years after the second kidney transplant, death-censored graft survival at five years for the second renal allograft was 90.6% for the BK group and 83.9% for non-BK group. In adjusted analysis, there was no difference in death-censored graft survival (p=0.11), acute rejection (p=0.49), and patient survival (p=0.13) between two groups. When we further compared death-censored graft survival among the specific causes for first graft failure, the BK group had better graft survival than patients who had prior allograft failure due to acute rejection (p<0.001) or disease recurrence (p=0.003), but similar to those with chronic allograft nephropathy (p=0.06) and other causes (p=0.05). The better allograft survival in the BK group over acute rejection and disease recurrence remained after adjusting for potential confounders. History of allograft loss due to BKVAN should not be a contraindication to retransplantation among candidates who are otherwise acceptable.